The "new" rules of engagement

How pharmaceutical companies can give HCPs the new and meaningful interactions they want.

Accenture Strategy & Consulting
With this survey, we sought to understand how healthcare provider (HCP) needs and expectations of pharmaceutical companies have evolved since the COVID-19 pandemic began, and which changes will have long-lasting implications for the way HCPs engage with pharma going forward.

Participants (N = 720)
The survey participants identified themselves as one of the following healthcare disciplines:

- **25%** General Practitioner
- **25%** Oncologist
- **25%** Immunologist
- **25%** Cardiologist

Countries
120 participants from each country: USA, UK, France, Germany, China & Japan.

The survey data was collected in May-June 2021.
An evolution of engagement

In our 2020 survey, HCPs said that COVID-19 was driving lasting change in what they need and value and how they want to engage with pharmaceutical companies. They indicated that pharma companies had shown improvement in both relevance and the support services they provide.

A year later, HCPs said that while the improvements were sustained, they still feel that more can be done to better understand their needs and the needs of their patients.

HCPs reward those companies who demonstrate this understanding with more of their time and attention. This, coupled with the fact that HCPs are seeing fewer patients, reveals an opportunity for pharma companies to gain time, trust and influence with HCPs and their patients.
Pharmaceutical companies are shifting to better engage HCPs but providers want more.

#1 Key Finding
Pharma companies need to do more to better understand and meet the expectations of HCPs due to COVID-19.

#2 Key Finding
When pharma companies do more, they are recognized and rewarded by HCPs with more time and attention.

#3 Key Finding
HCPs most value connections that blend the best of virtual and in-person, focused on the needs of their patients.
Pharma companies need to do more to better understand and meet the expectations of HCPs due to COVID-19.
Pharmaceutical companies are making strides towards more valuable and meaningful HCP interactions.

86% of HCPs have seen pharma companies change what they communicate about beyond product information to be “truly helpful”

83% of HCPs believe the content they are receiving from pharma companies today is more relevant than before the COVID-19 crisis...

33% ...with a third believing it is far more relevant.

Their content resonates more now than before COVID-19

They are more considerate of HCP’s most pressing needs
However, truly helpful content is getting lost in the communications clutter

While new messages from pharma companies are welcome, healthcare providers are also receiving high volumes of less relevant digital content that is missing the mark.

65% of HCPs feel at least one pharma company has “spammed” them with digital content as the COVID-19 pandemic has evolved.

77% Almost 8 in 10 HCPs are seeing a greater volume of information from pharma companies than pre-COVID-19.

64% of HCPs agree that the volume of digital communications they receive from pharma is too great.

2/3 Nearly two-thirds of HCPs agree that the volume of meetings they are invited to join is greater than they have time for.
HCPs still believe pharma companies could do more to better understand their evolving needs.

Almost 1 in 4 HCPs believe pharma companies do not understand at all or understand insufficiently their changing needs and expectations for patient treatment due to COVID-19.

This gap in understanding is as pronounced today as a year ago.

Most HCPs maintain the impression that pharma companies are failing to understand the real impact of COVID-19 on them (56%) and their patients (60%).
When pharma companies do more, they are recognized and rewarded by HCPs with more time and attention.
HCPs have more time available than before COVID-19.

The daily volume of patients they see in their practices continues to decrease.

3/4 of HCPs have seen a decrease in patient numbers over the past year and a third significantly so.

- Oncologist: 76%
- Immunologist: 78%
- Cardiologist: 72%
- General Practitioner: 73%

Most still have more capacity available than before COVID-19.

- Increased capacity: 61%
- Decreased capacity: 21%
- Capacity stayed the same: 9%
- Capacity did change but is now back to normal: 8%
HCPs are taking note of and recognizing those pharma companies who provide more meaningful engagements.

Almost 9 in 10 of HCPs acknowledge that some companies offer better engagements, with 41% noting “significantly so”.
HCPs are rewarding pharma companies that deliver positive interactions with more access.

They would be more willing to meet others if they were as good as their best relationship.

88% of HCPs have would be **twice as likely to meet with other companies/reps** if their best relationship were replicated.

Highly positive interactions make them more likely to engage with that company in some other way.

- 35% will **meet with different people** from that company in the future.
- 38% will be **more likely to meet** with that person/company again.
- 39% will **make more time** for that person/company next time we meet.
- 41% will **open e-mails and listen to messages** from that company more than others.
- 42% will be more likely to **engage** with that person/company in some other way.
#3 Key Finding

HCPs most value connections that blend the best of virtual and in-person, focused on the needs of their patients.
HCPs value content that helps them better serve their patients

Data plays a dominant role in shaping treatment decisions

59% of HCPs regarded technology-driven recommendations based on data, such as clinical trial and real-world data, as the most popular factor shaping their treatment decisions.
All indications are that virtual meetings are here to stay

Despite the lifting of travel restrictions in many countries, there has been no significant return to face-to-face meetings.

HCPs would prefer virtual engagement to continue after the COVID-19 pandemic ends.

Comparing the preferences before COVID-19, in mid-2020, and in mid-2021:

- **Virtual meetings**
  - Before COVID-19: 36%
  - In mid-2020: 65%
  - In mid-2021: 61%

- **In-person meetings**
  - Before COVID-19: 64%
  - In mid-2020: 35%
  - In mid-2021: 39%

Despite the lifting of travel restrictions in many countries, there has been no significant return to face-to-face meetings.

HCPs would prefer virtual engagement to continue after the COVID-19 pandemic ends.
Looking ahead
There is no single approach to success. Pharma companies will need to continuously challenge what defines relevance across the HCP landscape.

What HCPs find valuable when engaging with pharma companies differs across practices.

**General Practitioner**
Knowledge of when in my schedule it was most convenient to reach me.

**Oncologist**
Opportunities for me to collaborate and network with my peers.

**Immunologist**
A rapid response to my queries and needs.

**Cardiologist**
Interacting with me in an empathetic, authentic and personal way.
Pharma companies must seize the opportunity to test bold new ways of thinking and working

- Continuously challenge what defines relevance.
- Stop regarding the field force as a standalone channel.
- Minimize the content clutter.
Contacts

Laura Dix
Managing Director – Life Sciences
laura.e.dix@accenture.com

Suzy Jackson
Managing Director – Life Sciences
suzy.jackson@accenture.com

Ray Pressburger
Managing Director – Life Sciences
Lead, Commercial, Sales and Marketing
ramon.w.pressburger@accenture.com
About Accenture

Accenture is a leading global professional services company, providing a broad range of services in strategy and consulting, interactive, technology and operations, with digital capabilities across all of these services. We combine unmatched experience and specialized capabilities across more than 40 industries – powered by the world’s largest network of Advanced Technology and Intelligent Operations centers. With 505,000 people serving clients in more than 120 countries, Accenture brings continuous innovation to help clients improve their performance and create lasting value across their enterprises.

Visit us at www.accenture.com

DISCLAIMER: This document is intended for general informational purposes only and does not take into account the reader’s specific circumstances, and may not reflect the most current developments. Accenture disclaims, to the fullest extent permitted by applicable law, any and all liability for the accuracy and completeness of the information in this presentation and for any acts or omissions made based on such information. Accenture does not provide legal, regulatory, audit, tax or medical advice, and is not a manufacturer of medical devices. Readers are responsible for obtaining such advice from their own legal counsel or other licensed professionals.

Accenture Life Sciences
Patient Inspired. Outcomes Driven.

Accenture’s Life Sciences group is committed to helping our clients make a meaningful impact on patients’ lives by combining new science with leading edge technology to revolutionize how medical treatments are discovered, developed and delivered to people around the world. We provide end-to-end business services as well as broad range of insight-driven services and solutions in strategy, consulting, digital/analytics, technology and operations in all strategic and functional areas—with a strong focus on R&D, Sales & Marketing, Patient Services and the Supply Chain.

We have decades of experiences working with the world’s most successful companies to innovate and improve their performance and across the entire Life Sciences value chain to better serve patients and stakeholders. Accenture’s Life Sciences group connects more than 15,000 skilled professionals in over 50 countries who are personally committed to helping our clients achieve their business objectives and deliver better health and economic outcomes.

Follow us: